Search

Search Results

• 

  Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study

  Roberto Saldanha Jarimba, Miguel Nobre Eliseu, João Pedroso Lima, Vasco Quaresma, Pedro Moreira, Pedro Coelho Nunes, Edgar Tavares da Silva, Arnaldo José Figueiredo

  393-398

  20-12-2021

  https://doi.org/10.4081/aiua.2021.4.393

  1927

  Downloads: 1373

• Impact of statins on metastatic castration-resistant prostate cancer patients receiving new hormonal agents

  Ana Marta Ferreira, Tiago Sousa, Roberto Jarimba, Vasco Quaresma, Pedro Nunes, Edgar Tavares da Silva, Arnaldo Figueiredo

  03-11-2025

  https://doi.org/10.4081/aiua.2025.14179

  949

  Downloads: 545

• Prognostic value of Ki67 and PSA-immunostaining in de novo metastatic hormone-sensitive prostate cancer

  Ana Marta Ferreira, Roberto Jarimba, André Rego, João Gama, Rui Almeida, Miguel Eliseu, Vasco Quaresma, Pedro Nunes, Vitor Sousa, Arnaldo Figueiredo

  31-03-2026

  https://doi.org/10.4081/aiua.2026.14731

  328

  Downloads: 249
• 

  Prostate-specific antigen response after Abiraterone treatment in mCRPC: PSA as a predictor of overall survival

  Alexandre Mendonça Macedo, Rita Gameiro Marques, Margarida Cunha André, Nuno Silva Figueira, Miguel Leal Carvalho

  22-02-2023

  https://doi.org/10.4081/aiua.2023.11052

  1383

  Downloads: 1106

• The role of immunotherapy in urological cancers

  Efe Bosnali, Enes Malik Akdas, Engin Telli, Kerem Teke, Onder Kara

  30-05-2024

  https://doi.org/10.4081/aiua.2024.12307

  2830

  Downloads: 1754

• BRCA mutations and prostate cancer: should urologist improve daily clinical practice?

  Simona Vatrano, Pietro Pepe, Ludovica Pepe, Nuccia Vella, Cristina Alario, Alessia Chiarandà, Chiara Taranto, Renato Scillieri, Cristina Mauceri, Filippo Fraggetta

  17-04-2025

  https://doi.org/10.4081/aiua.2025.13635

  1951

  Downloads: 836
• 

  Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis

  Gianpaolo Perletti, Elena Monti, Emanuela Marras, Anne Cleves, Vittorio Magri, Alberto Trinchieri, Paul S. Rennie

  121-129

  07-07-2015

  https://doi.org/10.4081/aiua.2015.2.121

  11243

  Downloads: 6047

• Prognostic value of neutrophil-to-lymphocyte ratio in mCRPC patients treated with abiraterone, enzalutamide and docetaxel: a retrospective single-center study

  Ana Marta Ferreira, André Rego, Vasco Quaresma, Roberto Jarimba, Edgar Tavares da Silva, Pedro Nunes, Arnaldo Figueiredo

  07-08-2026

  https://doi.org/10.4081/aiua.2026.15630

  12

  Downloads: 7
• 

  C reactive protein/Albumin ratio as predictor of prognosis in castration resistant metastatic prostate cancer

  João Lorigo, Edgar Tavares Silva, João Pedroso Lima, Vasco Quaresma, Rui Pedrosa, Arnaldo Figueiredo

  11-07-2023

  https://doi.org/10.4081/aiua.2023.11242

  1306

  Downloads: 707
• 

  Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC

  Viviana Frantellizzi, Julia Lazri, Mariano Pontico, Arianna Pani, Giuseppe De Vincentis

  01-10-2020

  https://doi.org/10.4081/aiua.2020.3.196

  1234

  Downloads: 875
• 

  Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer

  Johann de Bono, Liji Shen, Oliver Sartor

  72-73

  31-03-2016

  https://doi.org/10.4081/aiua.2016.1.72

  2666

  Downloads: 1347
• 

  Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer

  Gianpaolo Perletti

  74-75

  31-03-2016

  https://doi.org/10.4081/aiua.2016.1.74

  1801

  Downloads: 1253